Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells

Abstract Despite recent advances in the therapy of diffuse large B‐cell lymphoma, not otherwise specified (DLBCL), around 30% of patients develop refractory disease or relapse after first‐line treatment. Recently, Ars2 was reported as the auto‐antigenic target of the B‐cell receptor (BCR) in approxi...

Full description

Bibliographic Details
Main Authors: Maximilian Kiefer, Lorenz Thurner, Theresa Bock, Onur Cetin, Igor Kos, Vadim Lesan, Dominic Kaddu‐Mulindwa, Joerg Thomas Bittenbring, Natalie Fadle, Evi Regitz, Markus Hoth, Frank Neumann, Klaus‐Dieter Preuss, Michael Pfreundschuh, Konstantinos Christofyllakis, Moritz Bewarder
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:eJHaem
Subjects:
autoantigen
BAR‐bodies
B cells
B‐cell receptor
lymphoid malignancies
Online Access:https://doi.org/10.1002/jha2.635

Internet

https://doi.org/10.1002/jha2.635

Similar Items